Overview

A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLC

Status:
Not yet recruiting
Trial end date:
2024-09-11
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of T-DXd in participants with HER2 mutant metastatic non-squamous NSCLC.
Phase:
Phase 2
Details
Lead Sponsor:
AstraZeneca
Collaborator:
Daiichi Sankyo, Inc.
Treatments:
Trastuzumab